Johnson & Johnson (NYSE:JNJ) has been given a $134.00 price target by equities researchers at Goldman Sachs in a research report issued on Tuesday. The brokerage presently has a “sell” rating on the stock. Goldman Sachs’ target price indicates a potential upside of 2.97% from the company’s previous close.
JNJ has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Monday, April 9th. Jefferies Group set a $153.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday. Vetr lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price objective for the company. in a research note on Monday, March 26th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Five analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $144.23.
NYSE:JNJ traded down $1.62 during mid-day trading on Tuesday, hitting $130.14. 5,578,553 shares of the company’s stock were exchanged, compared to its average volume of 7,869,039. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The company has a market cap of $350,440.66, a PE ratio of 17.83, a P/E/G ratio of 2.08 and a beta of 0.74.
In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.22% of the company’s stock.
Several large investors have recently modified their holdings of JNJ. Goodman Financial Corp bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $104,000. Harding Loevner LP bought a new position in Johnson & Johnson during the second quarter valued at approximately $106,000. Stelac Advisory Services LLC bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $108,000. IHT Wealth Management LLC grew its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson during the second quarter valued at approximately $124,000. 67.23% of the stock is currently owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.